Clinical Trial Update: CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CB-839 (telaglenastat) with capecitabine in fluoropyrimidine-resistant colorectal cancer and other solid tumors has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• CB-839 (telaglenastat)
• Capecitabine (capecitabine)

Snippet

Sponsor: David Bajor, MD | Conditions: Colorectal Cancer, Colon Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-19